HIV

A global AIDS program that was in limbo for months got temporary relief after congressional negotiators agreed to a 1-year renewal in the next government funding package; the outcome of the November presidential election could determine the state of fetal tissue research in the US; federal officials and industry executives failed to make improvements that stop hacking attacks.

Men who have sex with men (MSM) were found to engage in more risk behaviors when self-testing for HIV.

Men who have sex with men who are living with HIV tend to have fewer depressive symptoms if they report better family functioning.

The US government’s program to send free COVID-19 tests is ending later this week; a new study found that Ozempic (semaglutide) may lower liver disease risks in people living with HIV; scientists use cells from amniotic fluid to grow miniature organs.

A nurse-led strategy for people living with HIV was able to reduce both blood pressure and cholesterol in a 12-month period.

The higher burden of comorbidities in patients with both HIV and pulmonary hypertension (PH) led to worse outcomes, including mortality.

Patients with HIV who have suppressed viral loads and pre-existing resistance will be able to use bictegravir with this FDA approval.

Different levels of risk for HIV exist in the different subtypes of intellectual and developmental disabilities.

Pregnant women who are living with HIV are underrepresented in studies on the efficacy of vaccines, leading to difficult policy decisions for this population.

Strategies used during the COVID-19 pandemic to ensure continuity of care in people living with HIV can be used as a paradigm of adaptability during unexpected crises.

Although rates of opioid use disorder (OUD) are higher than previous estimates, OUD was relatively stable or decreasing over time in patients with HIV.

People living with HIV reported feeling inferiority due to HIV and gloomy feelings during the COVID-19 pandemic, as researchers linked internalized HIV stigma to depressive symptoms.

Separate machine learning models were able to effectively predict both the length of hospital stay and the risk of prolonged hospitalization in people living with HIV.

Patients living with HIV had a lower uptake of hepatitis A virus vaccination despite it being recommended for this population.

The deterioration of bones could contribute to the loss of teeth in women who are postmenopausal and living with HIV.

The researchers noted the need for strategies to better support women living with HIV with breast cancer during toxic therapies to improve outcomes among this growing population.

The top-read topics in HIV for 2023 included dried blood tests for HIV, people with HIV facing stigmas, and vitamin D supplementation in women with HIV.

The top 5 most-read news content for 2023 featured COVID-19 vaccination uptake and its relation to HIV viral suppression, those more likely to get vitamin D supplements, and recurrence of Clostridioides difficile infection.

From 2013 to 2022, the all-cause mortality rate among patients with HIV in China declined from 5.4% to 2.7%.

Infants with HIV could be spared from requiring lifetime antiretroviral (ART) if treated within hours of birth to disrupt formation of HIV viral reservoirs.

Negotiations to extend US global HIV/AIDS relief work are deadlocked; the Biden administration delayed its rule on the proposed menthol cigarette ban until March 2024 after lobbying by civil rights groups; federal agencies have partnered with a digital health company to create an at-home test-to-treat program for flu and COVID-19.

The researchers suggested prioritizing and optimizing HIV and general health services for children younger than age 5 living with HIV and receiving ART to help address their disproportionately poorer outcomes.

Research on HIV and aging should be the focus of future research as World AIDS Day brings the chronic illness to the forefront.

The Targeted Minimum Loss-based Estimation proved the most accurate capture-recapture model in estimating hidden populations of patients with HIV.

Patients who have HIV and are using antiretroviral therapy (ART) did not have adverse outcomes when using nivolumab for cancer treatment.